Latest article: |
|
|
Recent articles: |
|
Lonza Introduces Nucleofection® of Primary Neurons in Adherence
09 Mar 2010: Lonza’s Amaxa® Nucleofector® Technology offers the Nucleofection® of neurons directly in adherence with up to 60% transfection efficiency. The new Basic Neuron 96-well Nucleofector® AD Kit allows for pre- and post Nucleofection® culture of up to 14 days in which enables transfection of neurons at a later developmental stage.
Lonza Group Ltd
|
Lonza Announces Cells on Demand™ – Cell Culture and Transfection Services
03 Nov 2009: Lonza announces the launch of Cells on Demand™ Cell Culture and Transfection Services, a new offering providing researchers assay ready cells for cell based screening, including primary cells, cell lines, stable clones, transiently transfected cells and media.
Lonza Group Ltd
|
Expression Profiling of Cultured Hepatocytes using the StellARray Gene Expression System
27 Mar 2009: It is increasingly recognized that subsets of genes provide the most valuable gene profile definitions of any specific biological process. In this application article, Lonza demonstrates how the StellARray™ Gene Expression System helps researchers to focus on the gene "constellations" most relevant for their research areas. The system is also shown to protect gene expression profiling from unwanted bias caused by changes in 'housekeeping gene' expression.
Lonza Group Ltd
|
Expression Profiling of Cultured Hepatocytes challenged with Acetaminophine using the StellARray Gene Expression System
27 Mar 2009: Lonza introduces the StellARray™ Gene Expression System – a revolutionary qPCR array system that helps researchers to focus on the gene “constellations” most relevant for their research areas and that frees gene expression profiling from unwanted bias by changes in ‘housekeeping gene’ expression.
Lonza Group Ltd
|
Obtain High Transfection Efficiencies in Parasites
15 Aug 2008: Lonza has developed Amaxa® Basic Parasite Nucleofector® Kits providing transfection efficiencies of up to 1000 times higher (e.g. in Plasmodium berghei and Trypanosoma brucei) compared to standard methods such as electroporation or particle bombardment.
Lonza Group Ltd
|
Efficient Transfection of Human Chondrocytes
 31 Jul 2008: Nucleofection® allows efficient and reliable non-viral transfection of primary human chondrocytes with up to 74% transfection efficiency and up to 84% cell viability.
Lonza Group Ltd
|
New amaxa Stem Cell Kits Provide Transfection Efficiencies of up to 80%
26 Jun 2008: Embryonic stem cells are powerful tools for discovering developmental processes at the cellular level. Hence, amaxa introduces four new Human Stem Cell Nucleofector Kits, for single reactions and up to 96-well transfections, suitable for various stem cell lines.
Lonza Group Ltd
|
amaxa’s Online User Webinar - Efficient Transfection of Stem Cells
 12 May 2008: amaxa AG will host a free webinar on the Nucleofection® of Stem Cells which is scheduled for June 3rd (Europe, Japan) and June 4th (US).
Lonza Group Ltd
|
amaxa to Co-ordinate Collaboration to Develop High-throughput Devices for Primary Cell Transfection
02 Jul 2007: amaxa AG, a leading provider of transfection technologies to the life science community, has announced that it will co-ordinate a European collaboration of eight partners to develop devices for ultra high-throughput delivery and screening of primary cells, for use in the study of immunological, neuronal and liver disorders, for example.
Lonza Group Ltd
|
clinical diagnostics
